On a reported basis, annual sales rose from KRW 478.9 billion in 2022 to KRW 527 billion in 2023 (up 10.0% year on year), KRW 598.2 billion in 2024 (up 13.5%), and KRW 605.4 billion in 2025 (up 1.2%). Sales have increased for three consecutive years from 2023 through 2025, and 2025 was the largest year of 2022 to 2025.
Operating profit over the same period fell from KRW 43 billion in 2022 to KRW 32.2 billion in 2023 (down 25.1%), KRW 28.2 billion in 2024 (down 12.4%), and KRW 3.48 billion in 2025 (down 87.7%).
Operating profit has declined for three consecutive years from 2023 through 2025, and 2025 was the smallest year of the period. As a result, the operating margin fell from 9.0% in 2022 to 6.1%, 4.7% and 0.6% in 2025.
Sales grew while margins compressed, and the company attributed the first-half 2026 decline in operating profit to higher new-drug R&D and new-product marketing costs.
Net income attributable to controlling shareholders fell from KRW 31.9 billion in 2022 to KRW 23.9 billion in 2023 (down 25.1%) and KRW 14.2 billion in 2024 (down 40.6%), before swinging to a net loss of KRW 1.38 billion in 2025.
Total net income including non-controlling interests was a net loss of KRW 4.01 billion in 2025, a different figure from the controlling-shareholder measure.
Quarterly sales peaked at KRW 159.8 billion in 4Q 2025 and then fell to KRW 158.1 billion in 1Q 2026, KRW 152.8 billion in 2Q and KRW 139.3 billion in 3Q, three consecutive quarterly declines.
Operating profit moved from a KRW 10.4 billion loss in 3Q 2025 to KRW 5.85 billion profit in 4Q 2025, then KRW 4.38 billion in 1Q 2026 (down 25.2%), followed by an operating loss of KRW 8.92 million in 2Q and KRW 4.05 billion in 3Q, two straight loss-making quarters.
The 3Q 2026 loss was narrower than the KRW 10.4 billion loss a year earlier. Controlling-shareholder net income of KRW 13.6 billion in 4Q 2025 far exceeded that quarter's operating profit of KRW 5.85 billion, which suggests non-operating items may have had a large effect.
Controlling-shareholder net income for the last four quarters totaled KRW 13.2 billion. Operating cash flow was KRW 42.3 billion in 2025, well above the KRW 3.48 billion operating profit, so the gap between cash generation and earnings warrants attention.
Debt-to-equity was 123.5% at the end of 2025, with total liabilities of KRW 339.1 billion against total equity of KRW 274.6 billion, of which KRW 265.9 billion belongs to controlling shareholders.